Genetic insights in Alzheimer's disease

The Lancet Neurology

Volumn 12, Issue 1, 2013, Pages 92-104

  Bettens, Karolien ^a,b   Sleegers, Kristel ^a,b   Van Broeckhoven, Christine ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALLELE; ALZHEIMER DISEASE; EXOME; EXON; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; HUMAN; NEUROLOGIST; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH;

ALZHEIMER DISEASE; ANIMALS; GENETIC LINKAGE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS;

EID: 84870796993     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70259-4     Document Type: Review

References (129)

1. World Alzheimer Report 2009 Alzheimer's Disease International Consortium, (accessed Nov 13, 2012). http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf.
2. Braak H, Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
3. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
4. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269:973-977.
5. Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248:1124-1126.
6. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995, 376:775-778.
7. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
8. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006, 63:168-174.
9. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
10. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011, 43:429-435.
11. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099.
12. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011, 43:436-441.
13. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840.
14. Kasuga K, Shimohata T, Nishimura A, et al. Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease. J Neurol Neurosurg Psychiatry 2009, 80:1050-1052.
15. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006, 38:24-26.
16. Rovelet-Lecrux A, Frebourg T, Tuominen H, Majamaa K, Campion D, Remes AM APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007, 78:1158-1159.
17. Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006, 129:2977-2983.
18. Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
19. Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008, 63:377-387.
20. Hooli BV, Mohapatra G, Mattheisen M, et al. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 2012, 78:1250-1257.
21. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391:387-390.
22. Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 2006, 96:732-742.
23. Kumar-Singh S, Theuns J, Van Broeck B, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 2006, 27:686-695.
24. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996, 2:864-870.
25. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999, 65:664-670.
26. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997, 278:1349-1356.
27. Bickeboller H, Campion D, Brice A, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet 1997, 60:439-446.
28. Genin E, Hannequin D, Wallon D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011, 16:903-907.
29. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009, 41:1303-1307.
30. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
31. Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010, 42:234-239.
32. Guerreiro RJ, Lohmann E, Kinsella E, et al. Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease. Neurobiol Aging 2012, 33:1008-1023.
33. Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010, 68:857-864.
34. Watts GD, Thomasova D, Ramdeen SK, et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 2007, 72:420-426.
35. Rademakers R, Dermaut B, Peeters K, et al. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in western Europe. Hum Mutat 2003, 22:409-411.
36. Dermaut B, Kumar-Singh S, Engelborghs S, et al. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol 2004, 55:617-626.
37. Brouwers N, Nuytemans K, van der Zee J, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol 2007, 64:1436-1446.
38. Brouwers N, Sleegers K, Engelborghs S, et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 2008, 71:656-664.
39. Majounie E, Abramzon Y, Renton AE, et al. Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med 2012, 366:283-284.
40. Pottier C, Hannequin D, Coutant S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 2012, 17:875-879.
41. Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K SORL1 is geneticaly associated with increased risk for late-onset Alzheimer's disease in the Belgian population. Hum Mutat 2008, 29:769-770.
42. Reitz C, Cheng R, Rogaeva E, et al. Meta-analysis of the association between variants in SORL1 and Alzheimer's disease. Arch Neurol 2010, 68:99-106.
43. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007, 39:168-177.
44. Valdmanis PN, Belzil VV, Lee J, et al. A mutation that creates a pseudoexon in SOD1 causes familial ALS. Ann Hum Genet 2009, 73:652-657.
45. Theuns J, Brouwers N, Engelborghs S, et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 2006, 78:936-946.
46. Bettens K, Brouwers N, Engelborghs S, et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegen 2012, 7:3.
47. Cirulli ET, Singh A, Shianna KV, et al. Screening the human exome: a comparison of whole genome and whole transcriptome sequencing. Genome Biol 2010, 11:R57.
48. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nat Rev Neurol 2012, published online July 8. 10.1038/nrneurol.2012.158.
49. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804.
50. van der Zee J, Gijselinck I, Dillen L, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability and intermediate repeats. Hum Mutat 2012, published online Oct 30. 10.1002/humu.22244.
51. Carrasquillo MM, Belbin O, Hunter TA, et al. Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol 2010, 67:961-964.
52. Corneveaux JJ, Myers AJ, Allen AN, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 2010, 19:3295-3301.
53. Hu X, Pickering E, Liu YC, et al. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS One 2011, 6:e16616.
54. Jun G, Naj AC, Beecham GW, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 2010, 67:1473-1484.
55. Kamboh MI, Minster RL, Demirci FY, et al. Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol Aging 2010, 33:518-521.
56. Lee JH, Cheng R, Barral S, et al. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol 2011, 68:320-328.
57. Schjeide BM, Schnack C, Lambert JC, et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry 2011, 68:207-213.
58. Wijsman EM, Pankratz ND, Choi Y, et al. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet 2011, 7:e1001308.
59. Zhang Q, Yu JT, Zhu QX, et al. Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease. Brain Res 2010, 1348:216-221.
60. Schnetz-Boutaud NC, Hoffman J, Coe JE, Murdock DG, Pericak-Vance MA, Haines JL Identification and confirmation of an exonic splicing enhancer variation in exon 5 of the Alzheimer disease associated PICALM gene. Ann Hum Genet 2012, 76:448-453.
61. Antunez C, Boada M, Gonzalez-Perez A, et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's disease. Genome Med 2011, 3:33.
62. Carrasquillo MM, Belbin O, Hunter TA, et al. Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study. Mol Neurodegener 2011, 6:54.
63. Ross OA, Soto-Ortolaza AI, Heckman MG, et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol 2011, 10:898-908.
64. Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 2006, 48:718-728.
65. Szymanski M, Wang R, Bassett SS, Avramopoulos D Alzheimer's risk variants in the Clusterin gene are associated with alternative splicing. Transl Psychiatr 2011, 1:e18.
66. Guerreiro RJ, Beck J, Gibbs JR, et al. Genetic variability in CLU and its association with Alzheimer's Disease. PLoS One 2010, 5:e9510.
67. Thambisetty M, Simmons A, Velayudhan L, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010, 67:739-748.
68. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM Plasma clusterin and the risk of Alzheimer disease. JAMA 2011, 305:1322-1326.
69. IJsselstijn L, Dekker LJ, Koudstaal PJ, et al. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 2011, 10:2006-2010.
70. Schürmann B, Wiese B, Bickel H, et al. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 2011, 25:421-424.
71. Allen M, Zou F, Chai HS, et al. Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology 2012, 79:221-228.
72. Brouwers N, Van CC, Engelborghs S, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 2011, 17:223-233.
73. Lambert JC, Zelenika D, Hiltunen M, et al. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging 2011, 32:756-765.
74. Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010, 466:714-719.
75. Maher B Personal genomes: the case of the missing heritability. Nature 2008, 456:18-21.
76. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
77. Lupton MK, Proitsi P, Danillidou M, et al. Deep sequencing of the nicastrin gene in pooled DNA, the identification of genetic variants that affect risk of Alzheimer's disease. PLoS One 2011, 6:e17298.
78. Dermaut B, Theuns J, Sleegers K, et al. The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. Am J Hum Genet 2002, 70:1568-1574.
79. Hamilton G, Killick R, Lambert JC, et al. Functional and genetic analysis of haplotypic sequence variation at the nicastrin genomic locus. Neurobiol Aging 2012, 33:1848.
80. Liang Y, Buckley TR, Tu L, Langdon SD, Tedder TF Structural organization of the human MS4A gene cluster on chromosome 11q12. Immunogenetics 2001, 53:357-368.
81. de Silva HV, Stuart WD, Duvic CR, et al. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 1990, 265:13240-13247.
82. Kim WS, Weickert CS, Garner B Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem 2008, 104:1145-1166.
83. Kirszbaum L, Bozas SE, Walker ID SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett 1992, 297:70-76.
84. Khera R, Das N Complement Receptor 1: disease associations and therapeutic implications. Mol Immunol 2009, 46:761-772.
85. Jehle AW, Gardai SJ, Li S, et al. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol 2006, 174:547-556.
86. Jones L, Harold D, Williams J Genetic evidence for the involvement of lipid metabolism in Alzheimer's disease. Biochim Biophys Acta 2010, 1801:754-761.
87. Ivanov AI, Romanovsky AA Putative dual role of ephrin-Eph receptor interactions in inflammation. IUBMB Life 2006, 58:389-394.
88. Tebar F, Bohlander SK, Sorkin A Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999, 10:2687-2702.
89. Wigge P, Kohler K, Vallis Y, et al. Amphiphysin heterodimers: potential role in clathrin-mediated endocytosis. Mol Biol Cell 1997, 8:2003-2015.
90. Tateno H, Li H, Schur MJ, et al. Distinct endocytic mechanisms of CD22 (siglec-2) and siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol 2007, 27:5699-5710.
91. Lynch DK, Winata SC, Lyons RJ, et al. A cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem 2003, 278:21805-21813.
92. Nuutinen T, Suuronen T, Kauppinen A, Salminen A Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009, 61:89-104.
93. Hazrati LN, Van Cauwenberghe C, Brooks PL, et al. Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism. Neurobiol Aging 2012, 33:e5-12.
94. Keenan BT, Shulman JM, Chibnik LB, et al. A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum Mol Genet 2012, 21:2377-2388.
95. Harel A, Wu F, Mattson MP, Morris CM, Yao PJ Evidence for CALM in directing VAMP2 trafficking. Traffic 2008, 9:417-429.
96. Lambert JC, Grenier-Boley B, Chouraki V, et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis 2010, 20:1107-1118.
97. Thambisetty M, Hye A, Foy C, et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 2008, 255:1712-1720.
98. Kok EH, Luoto T, Haikonen S, Goebeler S, Haapasalo H, Karhunen PJ CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques. Alzheimers Res Ther 2011, 3:12.
99. Chibnik LB, Shulman JM, Leurgans SE, et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol 2011, 69:560-569.
100. Kauwe JS, Cruchaga C, Karch CM, et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS One 2011, 6:e15918.
101. Han MR, Schellenberg GD, Wang LS Genome-wide association reveals genetic effects on human Abeta42 and tau protein levels in cerebrospinal fluids: a case control study. BMC Neurol 2010, 10:90.
102. Kim S, Swaminathan S, Shen L, et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011, 76:69-79.
103. Treusch S, Hamamichi S, Goodman JL, et al. Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 2011, 334:1241-1245.
104. Shulman JM, Chipendo P, Chibnik LB, et al. Functional screening of Alzheimer pathology genome-wide association signals in Drosophila. Am J Hum Genet 2011, 88:232-238.
105. Biffi A, Anderson CD, Desikan RS, et al. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol 2010, 67:677-685.
106. Braskie MN, Jahanshad N, Stein JL, et al. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci 2011, 31:6764-6770.
107. Lancaster TM, Baird A, Wolf C, et al. Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene. Eur Neuropsychopharmacol 2011, 21:880-884.
108. Erk S, Meyer-Lindenberg A, Opitz von Boberfeld C, et al. Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. J Neurosci 2011, 31:18180-18184.
109. Bralten J, Franke B, Arias-Vasquez A, et al. CR1 genotype is associated with entorhinal cortex volume in young healthy adults. Neurobiol Aging 2011, 32:2106.e7. 2106.11.
110. Thambisetty M, Beason-Held LL, An Y, et al. Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry 2012, published online July 13. 10.1016/j.biopsych.2012.05.026.
111. Shen L, Kim S, Risacher SL, et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 2010, 53:1051-1063.
112. Furney SJ, Simmons A, Breen G, et al. Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry 2010, 16:1130-1138.
113. Stein JL, Medland SE, Vasquez AA, et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet 2012, 44:552-561.
114. Burkhardt R, Kenny EE, Lowe JK, et al. Common SNPs in HMGCR in Micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol 2008, 28:2078-2084.
115. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008, 40:189-197.
116. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
117. Hong MG, Pawitan Y, Magnusson PK, Prince JA Strategies and issues in the detection of pathway enrichment in genome-wide association studies. Hum Genet 2009, 126:289-301.
118. Hong MG, Reynolds CA, Feldman AL, et al. Genome-wide and gene-based association implicates FRMD6 in Alzheimer disease. Hum Mutat 2011, 33:521-529.
119. Lambert JC, Grenier-Boley B, Harold D, et al. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Mol Psychiatry 2012, published online March 20. 10.1038/mp.2012.14.
120. Barral S, Bird T, Goate A, et al. Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory. Neurology 2012, 78:1464-1471.
121. Farrer LA, Bowirrat A, Friedland RP, Waraska K, Korczyn AD, Baldwin CT Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Mol Genet 2003, 12:415-422.
122. Nalls MA, Guerreiro RJ, Simon-Sanchez J, et al. Extended tracts of homozygosity identify novel candidate genes associated with late-onset Alzheimer's disease. Neurogenetics 2009, 10:183-190.
123. Sims R, Dwyer S, Harold D, et al. No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2011, 156B:764-771.
124. Heinzen EL, Need AC, Hayden KM, et al. Genome-wide scan of copy number variation in late-onset Alzheimer's disease. J Alzheimers Dis 2010, 19:69-77.
125. Shaw CA, Li Y, Wiszniewska J, et al. Olfactory copy number association with age at onset of Alzheimer disease. Neurology 2011, 76:1302-1309.
126. Zuk O, Hechter E, Sunyaev SR, Lander ES The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci USA 2012, 109:1193-1198.
127. Zou F, Chai HS, Younkin CS, et al. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet 2012, 8:e1002707.
128. Yagi T, Ito D, Okada Y, et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet 2011, 20:4530-4539.
129. Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482:216-220.